Recurrences after nephron-sparing treatments of renal cell carcinoma: a competing risk analysis
World Journal of Urology · 07.08.2024 · 42 (1)
DOI: 10.1007/s00345-024-05172-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Urology, online erschienen am 07.08.2024. Verfasst von Andreas Karlsson Rosenblad und 4 weiteren Autor:innen. Beteiligte Einrichtung: Regional Cancer Centre Stockholm-Gotland, Region Stockholm, Stockholm, Sweden. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasm Recurrence, Local, Nephrectomy. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Umea University.
Abstract (Originalsprache)
Purpose
To examine associations between ablative therapy (AT) and partial nephrectomy (PN) and the occurrence of local recurrence (LR), distant metastatic recurrence (DMR) and all-cause mortality in a nation-wide real-world population-based cohort of patients with nonmetastatic renal cell carcinoma (nmRCC).
Methods
Data on 2751 AT- or PN-treated nmRCC tumours diagnosed during 2005–2018, representing 2701 unique patients, were obtained from the National Swedish Kidney Cancer Register. Time to LR/DMR or death with/without LR/DMR was analysed using Cox regression models.
Results
During a mean of 4.8 years follow-up, LR was observed for 111 (4.0%) tumours, DMR for 108 (3.9%) tumours, and death without LR/DMR for 206 (7.5%) tumours. AT-treated tumours had a 4.31 times higher risk of LR (P < 0.001) and a 1.91 times higher risk of DMR (P = 0.018) than PN-treated, with no significant differences in risk of death without LR/DMR. During a mean of 3.2 and 2.5 years of follow-up after LR/DMR, respectively, 24 (21.6%) of the LR cases and 56 (51.9%) of the DMR cases died, compared to 7.5% in patients without LR/DMR. There were no significant differences between AT- and PN-treated regarding risks of early death after occurrence of LR or DMR.
Conclusion
AT treatment of patients with nmRCC implied significantly higher risks of LR and DMR compared with PN treatment. To minimize the risks of LR and DMR, these results suggest that PN is preferred over AT as primary treatment, supporting the EAU guidelines to recommended AT mainly to frail and/or comorbid patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Regional Cancer Centre Stockholm-Gotland, Region Stockholm, Stockholm, Sweden.
- Department of Statistics, Uppsala University, Uppsala, Sweden.
- Department of Medical Sciences, Division of Clinical Diabetology and Metabolism, Uppsala University, Uppsala, Sweden.
- Department of Neurobiology, Care Sciences and Society, Division of Family Medicine and Primary Care, Karolinska Institutet, Stockholm, Sweden.
- Department of Surgical Sciences, Center for Clinical Research, County of Västmanland, Uppsala University, Uppsala, Sweden.
- Faculty of Medicine and Health, School of Medical Sciences, Örebro University, Örebro, Sweden.
Förderung
- Umea University
Zitieren
APA
Rosenblad, A. K., Hashim, B. M., Lindblad, P., Ljungberg, B., & National Swedish Kidney Cancer Register Steering Committee (2024). Recurrences after nephron-sparing treatments of renal cell carcinoma: a competing risk analysis. World Journal of Urology, 42(1). https://doi.org/10.1007/s00345-024-05172-1
Vancouver
Rosenblad AK, Hashim BM, Lindblad P, Ljungberg B, National Swedish Kidney Cancer Register Steering Committee. Recurrences after nephron-sparing treatments of renal cell carcinoma: a competing risk analysis. World Journal of Urology. 2024;42(1). doi:10.1007/s00345-024-05172-1
BibTeX
@article{Rosenblad2024,
author = {Rosenblad, Andreas Karlsson and Hashim, Bassam Mazin and Lindblad, Per and Ljungberg, Börje and National Swedish Kidney Cancer Register Steering Committee, National Swedish Kidney Cancer Register Steering Committee},
title = {Recurrences after nephron-sparing treatments of renal cell carcinoma: a competing risk analysis},
journal = {World Journal of Urology},
year = {2024},
volume = {42},
number = {1},
doi = {10.1007/s00345-024-05172-1}
}
EUVIMED